CHAPTER 6 of Cryme Disease
The Lyme Crooks' RICO
patents tell a very different story from their public one...
This is data
the Lyme crooks (Yale/NYMC/ALDF/IDSA/Kaiser
cabal) refused to turn over to the Connecticut Attorney General for a
year and a half before settling
out of court.
1) Yale's Bb
Flagellin Patent (an FDA-validated method), 5.618,533
LYMErix Patent, 5,747,294
Their validated method was not used to assess their LYMErix patent.
UCONN, 5,620,862 B31 = Low or No OspC- associated with brain
officer Alan Barbour and "Immune System is Overhwhelmed," US Patent
6,719,983- (because Lyme
is relapsing fever and the nature of the relapse is that antibodies do
Huber, 6,689,364 "LYMErix is a toxin"
Mayo Clinic, Monopoly Patent-6,045,804
CDC's patents with SmithKline in Europe which shows they know the Steere
method is bogus.
flagella-less borrelia patent
9) 1996 B. theileri patent (Master's
Disease is Cow Relapsing Fever)
Barbour patent application for Masters' Disease 5,932,220
How to verify- How to use the US Patent Database:
US Patent Office
http://patft1.uspto.gov/netahtml/PTO/search-bool.html Main Search page
http://patft1.uspto.gov/netahtml/PTO/srchnum.htm Patent Number Search
1) Yale explains how LYMErix does not work:
2) Yale not using DNA primers for flagellin to determine OspA "works":
They should not have used immunofluorescing antibodies, because OspA would no longer around due to "selection pressure"
3) Yale discussing how LYMErix does not prevent Lyme because of the
selection pressure, which essentially means that Lyme is a relapsing fever
borreliosis, since they all are relapsing fever borrelioses. 4 days
previously Yale applied for the LYMErix patent- even though they knew LYMErix
did not work:
THE RICO PATENTS
Yale's Bb Flagellin Patent,
5.618,533 94.4% accurate,
earliest, and likely nearly 100% specific, or is the best antibody test for Lyme
The Yale report that goes with the patent (1991):
Yale's LYMErix Patent,
5,747,294, Yes I know these by heart
Check out the date the patent was applied for. It was 4 days before Yale
sent for publication, the article where they explain how LYMErix would not work.
5,620,862 Low or No OspC. Yet SmithKline
and Quest used/use B31, which means OspA, B and C will not be identified if you
have those antbodies, and they are the "primary immunodominant antigens."
"In another aspect of the invention, Northern blot analysis was used to
detect low levels of OspC mRNA in the North American strain B31. DNA sequencing
of the OspC gene from B31 revealed a 54 bp deletion in the upstream regulatory
region, possibly accounting for the low transcriptional activity of OspC."
That SmithKline and Quest use
strain B31 is a crime, especially since the IgM method allowed by Dearborn
allows two of the following three antibodies: 41, 39 and 23, which is OspC.
Barbour and "Immune System Overhwhelmed," US Patent
"2.1 Methods of Treatment
"An important aspect of the invention is the recognition that Borrelia VMP-like
sequences recombine at the vls site, with the result that antigenic variation is
virtually limitless. Multiclonal populations therefore can exist in an infected
patient so that immunological defenses are severely tested if not totally
That means the Yale/Steere/Dearborn method is useless
for people who do not have Steere's haplotypes.
"The present invention provides novel polypeptides which are substantially
free of a B. burgdorferi spirochete or fragments thereof and which are thus
useful in compositions and methods for the treatment and prevention of B.
burgdorferi infection and Lyme disease. In one preferred embodiment, this
invention provides modified OspA polypeptides and pharmaceutically effective
compositions and methods comprising those polypeptides. Preferred modified OspA
polypeptides are characterized by modifications which diminish and/or ablate
their ability to bind the human MHC allele HLA-DRB1*0401."
Means, basically, "superantigen." (Look up what that
6) The RICO Monopoly on testing and LYMErix
The Dave Persing, Mayo Clinic FRAUD Patent-6,045,804 Note the
date on the patent. May, 1996.
"Additional uncertainty may arise if the vaccines are not
completely protective; vaccinated patients with multisystem complaints
characteristic of later presentations of Lyme disease may be difficult to
distinguish from patients with vaccine failure."
"The present invention provides
a method useful to detect a B. burgdorferi infection in a subject. The method
provided by the invention is particularly useful to discriminate B.
burgdorferi infection from OspA vaccination, although it is sufficiently
sensitive and specific to use in any general Lyme disease screening or
diagnostic application. Thus, the method of the invention is particularly
appropriate for large scale screening or diagnostic applications where only
part of the subject population has been vaccinated or where the vaccination
status of the population is unknown. "
(Or, appropriate for a
monopoly on vaccines and testing.)
Persing, Sigal and Molloy,
2000, and the unreadable blots
Yale's Robert Schoen
instructing physicians to blow off LYMErix injured persons and not run any tests
on them. This is the 1998 Rahn and Evans textbook Lyme disease, ACP Key Diseases Series. This was published even before LYMErix was
"approved" by the FDA. Schoen also demonstrates that he knows that you
can't use a strain of Bb with the OspA-B plasmid in it, because it causes blot
smudging or IS A SUPERANTIGEN???
The vaccine did not come off the market until Karen Forschner of
the Lyme disease Foundation http://www.lyme.org
demonstrated the Huber Tufts patent above to the FDA and that they KNEW
this vaccine was dangerous.
27) Martin J. Mattessich
President & CEO, Director
“Prior to becoming President
and CEO of Agilix, from 1996 to 1999 Mr. Mattessich was the co-founder of two
Yale University-sponsored biotechnology companies, L2 Diagnostics, LLC
(diagnostic serology) and polyGenomics, Inc. (gene discovery for polygenic
diseases) , and a consultant to CuraGen
Corporation, a publicly held genomics company (pharmaceutical drug ….”
the blood he intended to get from the L2 Diagnostics-Imugen nationwide
monopoly on testing, they can identify new diseases to commercialize.
AND genetic susceptibilities to diseases.
CHAPTER 8, RUSSIAN SCIENTISTS
AT NYMC (speaking about their "non-intracellular intracellular spheroplasts")